Short Information | Cel-Sci Corporation (NYSE:CVM)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 50,408 |
Total Actual Volume | 4,843,648 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 2,520 |
Average Short Percentage | 0.97% |
Is there a CVM Short Squeeze or Breakout about to happen?
See the CVM Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-03-2024 | $1.12 | $1.1 | $1.13 | $1.09 | 54,746 | 133 | 0.24% |
07-02-2024 | $1.13 | $1.09 | $1.14 | $1.08 | 214,333 | 286 | 0.13% |
07-01-2024 | $1.17 | $1.13 | $1.1802 | $1.08 | 364,978 | 5,376 | 1.47% |
06-28-2024 | $1.2 | $1.16 | $1.2 | $1.12 | 225,823 | 75 | 0.03% |
06-27-2024 | $1.19 | $1.18 | $1.22 | $1.14 | 155,072 | 149 | 0.1% |
06-26-2024 | $1.24 | $1.16 | $1.24 | $1.14 | 231,129 | 216 | 0.09% |
06-25-2024 | $1.23 | $1.23 | $1.2478 | $1.2 | 129,302 | 94 | 0.07% |
06-24-2024 | $1.3 | $1.23 | $1.3 | $1.2001 | 221,928 | 356 | 0.16% |
06-21-2024 | $1.25 | $1.29 | $1.3 | $1.21 | 295,516 | 1,697 | 0.57% |
06-20-2024 | $1.16 | $1.23 | $1.245 | $1.15 | 336,083 | 3,014 | 0.9% |
06-18-2024 | $1.31 | $1.11 | $1.3423 | $1.1 | 732,933 | 6,243 | 0.85% |
06-17-2024 | $1.28 | $1.25 | $1.3 | $1.25 | 207,046 | 9,886 | 4.77% |
06-14-2024 | $1.27 | $1.3 | $1.31 | $1.27 | 147,545 | 6 | 0% |
06-13-2024 | $1.35 | $1.29 | $1.36 | $1.29 | 152,615 | 179 | 0.12% |
06-12-2024 | $1.37 | $1.33 | $1.38 | $1.3 | 141,066 | 1,430 | 1.01% |
06-11-2024 | $1.27 | $1.36 | $1.36 | $1.27 | 239,265 | 4,667 | 1.95% |
06-10-2024 | $1.32 | $1.28 | $1.37 | $1.27 | 206,543 | 4,844 | 2.35% |
06-07-2024 | $1.29 | $1.3 | $1.3 | $1.25 | 130,597 | 2,059 | 1.58% |
06-06-2024 | $1.31 | $1.28 | $1.32 | $1.25 | 240,891 | 4,246 | 1.76% |
06-05-2024 | $1.21 | $1.27 | $1.34 | $1.18 | 416,237 | 5,452 | 1.31% |
News, Short Squeeze, Breakout and More Instantly...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...